welcome
CNBC

CNBC

Health

Health

Merck CEO Robert Davis goes one-on-one with Jim Cramer

CNBC
Summary
Nutrition label

59% Informative

Rob Davis is the chairman, president and CEO of Merck .

The number of phase three drugs in their pipeline has tripled versus 3 years ago .

The breadth and depth of the pipeline is, is the most diversified in the company's recent history, he says.

Davis : "I would no longer think of us as a Keytruda company. We are an oncology company".

Cramer: China is still an opportunity, but increasingly we're looking to how we go beyond in China broadly and frankly beyond Gardasil to the breadth of the portfolio we have.

We just did a deal to bring in an oral GLP , one small molecule.

We're we're focused oral small molecules and that really probably will be out for us into the early twenty 40s .

VR Score

55

Informative language

51

Neutral language

50

Article tone

informal

Language

English

Language complexity

30

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links